Peritoneal Cancer
IMGN853-0421: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
- Details
ClinicalTrials.gov ID:
NCT05445778
Diagnosis Type:
NA
USOR Number:
- Address
,
P: